INCYTE CORP

Incyte Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics, focused in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. The company's portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products JAKAFI, ICLUSIG, PEMAZYRE, OPZELURA, MINJUVI/MONJUVI, ZYNYZ, as well as NIKTIMVO which is co-commercialized. Incyte's operations are treated as one operating segment.

Incyte faces intense competition from organizations such as pharmaceutical and biotechnology companies, as well as academic and research institutions. The company's ability to compete successfully depends on its ability to develop proprietary products, develop and maintain products that reach the market first, are technologically superior or of lower cost, execute its strategic plan, attract and retain personnel, obtain patent protection, obtain regulatory approvals, and manufacture, market, distribute and sell products. The company has received notice letters from generic manufacturers challenging patents covering JAKAFI and OPZELURA, and has filed patent infringement actions in response.

Incyte generates revenue through product sales, product royalty revenues, and milestone and contract revenues. Product revenues are recognized net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, patient assistance programs, and government rebates. Product royalty revenues are earned on commercial sales of JAKAVI and TABRECTA by Novartis and OLUMIANT by Lilly. Milestone and contract revenues are derived from upfront payments and developmental milestones from third-party collaborators.

Incyte's hematology franchise includes four approved products: JAKAFI (ruxolitinib), approved for myelofibrosis, polycythemia vera, and graft-versus-host disease; ICLUSIG (ponatinib), approved in the European Union for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI (tafasitamab), approved for relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; and NIKTIMVO (axatilimab-csfr), approved for chronic GVHD. The company also has clinical programs in hematology including JAKAFI XR, INCA033989 (mutCALR), INCA035784 (mutCALRxCD3 bispecific), and INCB160058 (JAK2V617Fi).

Incyte's oncology franchise includes two approved products: PEMAZYRE (pemigatinib), approved for cholangiocarcinoma and myeloid/lymphoid neoplasms; and ZYNYZ (retifanlimab-dlwr), approved for Merkel cell carcinoma and squamous cell carcinoma of the anal canal. The Inflammation and Autoimmunity franchise includes OPZELURA (ruxolitinib) cream, approved for atopic dermatitis and vitiligo. Clinical programs in oncology include INCB123667 (CDK2), INCB161734 (KRAS G12D), and INCA33890 (TGFβR2xPD-1). Clinical programs in IAI include ruxolitinib cream for hidradenitis suppurativa and povorcitinib for hidradenitis suppurativa, nonsegmental vitiligo, prurigo nodularis, and asthma.

In February 2024, Incyte entered into a purchase agreement with MorphoSys AG to acquire exclusive global rights to tafasitamab, making a payment of $25.0 million ¹. In May 2024, the company acquired all outstanding shares of Escient Pharmaceuticals, Inc. for $782.5 million ² cash consideration. In May 2024, the Board of Directors approved a share repurchase authorization of $2.0 billion ³, and the company subsequently repurchased 33,325,849 ⁴ common shares at a price of $60.00 ⁵ per share for an aggregate purchase price of approximately $2.0 billion ⁶. In November 2025, Incyte entered into an exclusive purchase option agreement with Prelude Therapeutics Incorporated, paying a total of $60.0 million ⁷, comprised of an upfront payment of $35.0 million ⁸ plus a $25.0 million ⁹ equity investment. In May 2025, Incyte and Novartis entered into a settlement agreement, paying Novartis $280.0 million ¹⁰ as settlement of disputed royalties and agreeing to reduce by 50% ¹¹ the royalty rate payable on future net sales of JAKAFI in the United States.

Total revenues for the year ended December 31, 2025 were $5,141.2 million ¹², compared to $4,241.2 million ¹³ in 2024. Net income for 2025 was $1,286.7 million ¹⁴, compared to $32.6 million ¹⁵ in 2024. Basic net income per share was $6.59 ¹⁶ and diluted net income per share was $6.41 ¹⁷ for 2025, compared to basic net income per share of $0.16 ¹⁸ and diluted net income per share of $0.15 ¹⁹ for 2024. Total product revenues, net were $4,354.3 million ²⁰ in 2025, up from $3,618.9 million ²¹ in 2024. Total product royalty revenues were $636.9 million ²² in 2025, compared to $579.3 million ²³ in 2024.

A key growth vector is the development and potential commercialization of JAKAFI XR, a once-a-day formulation of ruxolitinib. In early 2025, the company announced that a bioequivalence study of ruxolitinib XR was completed and the bioequivalence criteria were met. A response to the complete response letter has been submitted and the company anticipates a regulatory decision and potential commercial launch in mid-2026 ²⁴. Another growth vector is INCA033989, an investigational anti-mutant CALR-targeted monoclonal antibody. In December 2025, the FDA granted Breakthrough Therapy designation to INCA033989 for the treatment of patients with ET harboring a Type 1 CALR mutation. The initiation of a Phase 3 trial evaluating INCA033989 in ET is anticipated in mid-2026 ²⁵, and the planned initiation of a Phase 3 trial in MF is anticipated in the second half of 2026 ²⁶.

Another growth vector is the expansion of tafasitamab into first-line therapy for DLBCL. In January 2026, the company announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating tafasitamab and lenalidomide in combination with R-CHOP as a first-line therapy for patients with DLBCL. Based on these positive results, the company expects to file a supplemental Biologics License Application in the first half of 2026 ²⁷. Additionally, the company is advancing INCB123667 (CDK2) for ovarian cancer, with the initiation of a Phase 3 study in first-line maintenance ovarian cancer anticipated in 2026 ²⁸, and INCB161734 (KRAS G12D) for pancreatic ductal adenocarcinoma, with a Phase 3 study anticipated to initiate in the first quarter of 2026 ²⁹.

The filing discusses the impact of the settlement agreement with Novartis on cost of product revenues. Under the settlement, the royalty rate payable by Incyte on future net sales of JAKAFI in the United States was reduced by 50% ³⁰ beginning January 1, 2025. The reduced royalty paid for the quarter ended March 31, 2025 was approximately $14.9 million ³¹. The difference of $242.2 million ³² between the total accrued royalties and the total amount paid to Novartis was recorded in contract dispute settlement on the consolidated statement of operations for the year ended December 31, 2025.

The company's manufacturing strategy for small molecule products is to contract with third parties to manufacture raw materials, active pharmaceutical ingredients, and finished dosage form. For large molecule products, the strategy is a combination of contracts with third parties and internal manufacturing. The company has a large molecule production facility in Yverdon, Switzerland, which started to manufacture MONJUVI/MINJUVI drug substance during the fourth quarter of 2022. The drug substance was granted regulatory approval for the European market in the fourth quarter of 2023 and for the United States in the third quarter of 2025 ³³. The company had 2,844 ³⁴ employees as of December 31, 2025, representing an increase of approximately 9% ³⁵ over the 2,617 ³⁶ employees as of the end of the prior year.

Research and development expenses for the year ended December 31, 2025 were $2,050.2 million ³⁷, compared to $2,606.8 million ³⁸ in 2024. Capital expenditures for 2025 were $58.9 million ³⁹, compared to $86.3 million ⁴⁰ in 2024. In August 2021, the company entered into a $500.0 million ⁴¹ senior unsecured revolving credit facility, which was subsequently amended to extend the maturity date to June 2027 ⁴². As of December 31, 2025, the company had no outstanding borrowings under this facility. The company has never declared or paid dividends on its capital stock and does not anticipate paying any dividends in the foreseeable future.

The company faces structural headwinds from the expected decline in JAKAFI product sales upon the expiration of patent exclusivity in 2028 ⁴³. The company anticipates that JAKAFI product sales will continue to contribute a significant percentage of total revenues over the next several years, but expects that these sales will begin to decline upon the expiration of patent exclusivity. The company also faces headwinds from government and third-party payor initiatives to manage drug costs, including the Inflation Reduction Act of 2022, which allows the federal government to negotiate prices for certain high-expenditure single source Medicare drugs and imposes rebate liability on manufacturers that take price increases that exceed inflation.

The company faces constraints from the concentration of credit risk related to its product revenues, with five customers (Customers A, B, C, D, and E) comprising 13% ⁴⁴, 9% ⁴⁵, 21% ⁴⁶, 18% ⁴⁷, and 11% ⁴⁸ of total net product revenues for the year ended December 31, 2025, respectively. The company also faces risks related to its reliance on third-party manufacturers, with a single source or limited number of suppliers qualified to supply each of the raw materials, API, and finished product of its drug products. For ruxolitinib phosphate, the API for JAKAFI and OPZELURA, the company has three qualified third-party contract manufacturers.

The company depends heavily on JAKAFI/JAKAVI (ruxolitinib), and if it is not able to maintain revenues from JAKAFI/JAKAVI or those revenues decrease, its business may be materially harmed. The company expects that JAKAFI product sales will begin to decline upon the expiration of its patent exclusivity in 2028 ⁴⁹. The company has received notice letters from generic manufacturers challenging patents covering JAKAFI and OPZELURA, and the entry of a competitive drug product or a generic version could result in a decrease in sales. The company is also subject to risks from healthcare reform measures, including the Inflation Reduction Act of 2022, which includes provisions allowing the federal government to negotiate prices for certain high-expenditure single source Medicare drugs and imposes rebate liability on manufacturers that take price increases that exceed inflation. The company faces risks related to its reliance on a limited number of specialty pharmacies and wholesalers for a significant portion of revenues from JAKAFI and most of its other drug products, with five customers comprising 72% ⁵⁰ of total net product revenues in 2025. The company also faces risks from its reliance on third-party manufacturers, with a single source or limited number of suppliers for each of its drug products, and raw materials used to manufacture ruxolitinib phosphate are supplied by Chinese-based companies.

Management's message emphasizes the company's focus on three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. The company highlights its portfolio of approved products and clinical development programs, noting that its revenues depend on continued sales of its products, and it depends substantially on product revenues from JAKAFI. Management states that the company must develop and commercialize new products to achieve revenue growth and to offset revenue losses from the loss of product exclusivity of JAKAFI in 2028 and the launch of competing products. The company devotes substantial resources to research and development activities and to acquire rights to new product candidates and technologies, but acknowledges that successful product development in the biopharmaceutical industry is highly uncertain.